The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Can ctDNA guide cetuximab sequencing and re-challenge strategies in MSS mCRC?
Giulia Martini, MD, PhD, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy, comments on results from the CAPRI-2 GOIM trial (NCT05312398) evaluating plasma circulating tumor DNA (ctDNA) comprehensive genomic profiling to guide sequential cetuximab-based therapy in RAS/BRAF wild-type microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Genomic profiling at baseline and following first-line treatment allowed for selection of patients that could really respond to EGFR-targeted treatment. In the trial, later lines of treatment could be selected, so hyperselection could help clinicians select patients for re-challenge strategies. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
